Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Research in context by Podjanee Jittamala, Simon Boyd, William H.K. Schilling, James A. Watson, Thundon Ngamprasertchai, Tanaya Siripoon, Viravarn Luvira, Elizabeth M. Batty, Phrutsamon Wongnak, Lisia M. Esper, Pedro J. Almeida, Cintia Cruz, Fernando R. Ascencao, Renato S. Aguiar, Najia K. Ghanchi, James J. Callery, Shivani Singh, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Wanassanan Madmanee, Kanokon Suwannasin, Amornrat Promsongsil, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Manus Potaporn, Attasit Srisubat, Bootsakorn Loharjun, Walter R.J. Taylor, Farah Qamar, Abdul Momin Kazi, M. Asim Beg, Danoy Chommanam, Sisouphanh Vidhamaly, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P.J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White

Subjects: Get full text